Evidence map›Paper›PMID 28487471›Full record

Trial reportClinical science (London, England : 1979)2017

Using DTI to assess white matter microstructure in cerebral small vessel disease (SVD) in multicentre studies.

Iain D Croall, Valerie Lohner, Barry Moynihan, Usman Khan, Ahamad Hassan, John T O'Brien, Robin G Morris, Daniel J Tozer, Victoria C Cambridge, Kirsty Harkness and 5 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical science (London, England : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Two distinct patterns of progression of sporadic cerebral small vessel disease.International journal of stroke : official journal of the International Stroke Society · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Iain D CroallDepartment of Clinical Neuroscience, Stroke Research Group, University of Cambridge, Cambridge, U.K.
Valerie LohnerDepartment of Clinical Neuroscience, Stroke Research Group, University of Cambridge, Cambridge, U.K.
Barry MoynihanNeurosciences Research Centre, St. George's, University of London, London, U.K.
Usman KhanStroke and Dementia Research Centre, St George's, University of London, London, U.K.
Ahamad HassanDepartment of Neurology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, U.K.
John T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, U.K.
Robin G MorrisDepartment of Psychology, Kings' College London, Institute of Psychiatry, Psychology and Neuroscience, London, U.K.
Daniel J TozerDepartment of Clinical Neuroscience, Stroke Research Group, University of Cambridge, Cambridge, U.K.
Victoria C CambridgeDepartment of Clinical Neuroscience, Stroke Research Group, University of Cambridge, Cambridge, U.K.
Kirsty HarknessDepartment of Neurology, Royal Hallamshire Hospital, Sheffield, U.K.
David J WerringDepartment of Brain Repair and Rehabilitation, Stroke Research Centre, UCL Institute of Neurology, London, U.K.
Andrew M BlamireMagnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, U.K.
Gary A FordMedical Sciences Division, University of Oxford, Oxford, U.K., & Oxford University Hospitals NHS Foundation Trust.
Thomas R BarrickMolecular and Clinical Science Research Institute, St George's, University of London, London, U.K.
Hugh S MarkusDepartment of Clinical Neuroscience, Stroke Research Group, University of Cambridge, Cambridge, U.K. hsm32@medschl.cam.ac.uk.
Bridge University · SSOxford University Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffusion tensor imaging (DTI) metrics such as fractional anisotropy (FA) and mean diffusivity (MD) have been proposed as clinical trial markers of cerebral small vessel disease (SVD) due to their associations with outcomes such as cognition. However, studies investigating this have been predominantly single-centre. As clinical trials are likely to be multisite, further studies are required to determine whether associations with cognition of similar strengths can be detected in a multicentre setting. One hundred and nine patients (mean age =68 years) with symptomatic lacunar infarction and confluent white matter hyperintensities (WMH) on MRI was recruited across six sites as part of the PRESERVE DTI substudy. After handling missing data, 3T-MRI scanning was available from five sites on five scanner models (Siemens and Philips), alongside neuropsychological and quality of life (QoL) assessments. FA median and MD peak height were extracted from DTI histogram analysis. Multiple linear regressions were performed, including normalized brain volume, WMH lesion load, and n° lacunes as covariates, to investigate the association of FA and MD with cognition and QoL. DTI metrics from all white matter were significantly associated with global cognition (standardized β =0.268), mental flexibility (β =0.306), verbal fluency (β =0.376), and Montreal Cognitive Assessment (MoCA) (β =0.273). The magnitudes of these associations were comparable with those previously reported from single-centre studies found in a systematic literature review. In this multicentre study, we confirmed associations between DTI parameters and cognition, which were similar in strength to those found in previous single-centre studies. The present study supports the use of DTI metrics as biomarkers of disease progression in multicentre studies.

Indexed as

Diffusion Tensor ImagingMagnetic Resonance ImagingAgedCerebral Small Vessel DiseasesCognitionCognition DisordersDisease ProgressionEnglandFemaleHumansLeukoencephalopathiesLinear ModelsMaleMicrovesselsMiddle AgedNeuropsychological Testsbiomarkerscerebral small vessel diseaseclinical trialscognitiondiffusion tensor imaging

Identifiers

PMID28487471
PMCPMC5461938
OpenAlexW2612583120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.